Eli Lilly and Merck beat estimates and raise outlooks
Eli Lilly beat Wall Street estimates and raised its sales outlook, citing resilient demand for its GLP-1 drugs. Its shares rose about 6% Thursday. Merck also topped estimates and lifted its profit forecast, helped by strength in its injectable version of the cancer drug Keytruda.
Read the original reporting
- CNBC (cnbc.com)
- Yahoo Finance (finance.yahoo.com)
This summary is written in our own words with the help of AI from the sources above. Please read the original reports for full detail. Spotted a mistake? Write to [email protected].